Wendy D. Carazo, PA-C

Wendy Carazo practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Wendy Carazo's NPI, 1629588777, was assigned on October 3, 2017. Wendy Carazo holds Texas license PA11525.

Wendy Carazo's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Wendy Carazo's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is UT Physicians. Dmand AI also links Wendy Carazo to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Wendy Carazo practices. Vendor and product names are available with a free account.

Physician assistant is Wendy Carazo's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Wendy Carazo is licensed in Texas.

Dmand AI lists acute skin infection among the conditions Wendy Carazo treats.

CMS data shows 47 Medicare services from Wendy Carazo across 3 procedure codes in 2024, for 113 Medicare patients. Medicare paid $2,842 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 113 Medicare patients who saw Wendy Carazo in 2024. The largest group is 65 to 74, with 52 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Wendy Carazo's median patient age at 72, with 38% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Wendy Carazo for performance year 2024, reported as part of a group. Wendy Carazo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Wendy Carazo as offering telehealth.

CMS Open Payments shows 4 general payments to Wendy Carazo from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Abbott Laboratories paid the most, $225.